[EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
申请人:BORAGEN INC
公开号:WO2021061823A1
公开(公告)日:2021-04-01
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.
Fast Titanium‐Catalyzed Hydroaminomethylation of Alkenes and the Formal Conversion of Methylamine
作者:Jens Bielefeld、Sven Doye
DOI:10.1002/anie.202001111
日期:2020.4.6
The scientific interest in catalytic hydroaminoalkylation reactions of alkenes has vastly increased over the past decade, but these reactions have struggled to become a viable option for general laboratory or industrial use because of reaction times of several days. The titanium-based catalytic system introduced in this work not only reduces the reaction time by several orders of magnitude, into the
Copper(II) porphyrin-catalyzed coupling of alkyl tosylates and alkyl Grignard reagents afforded substituted alkanes. The role of the copper(II) porphyrin complex was examined using EPR and in-situ ...
铜 (II) 卟啉催化的甲苯磺酸烷基酯和烷基格氏试剂的偶联得到取代的烷烃。使用 EPR 和原位...